# Stoke Therapeutics Shares Drop as Head Leaves
### Main Points
* The value of Stoke Therapeutics’ stock decreased on Tuesday after the declaration of the CEO’s resignation.
* Dr. Edward Kaye is scheduled to vacate his post on Wednesday, and the firm has already started the hunt for a replacement.
* Stoke’s fourth-quarter outcomes surpassed anticipations, with greater income and smaller deficits than predicted.
Shares of Stoke Therapeutics (STOK), a drug business, saw a reduction on Tuesday after the business disclosed that its Chief Executive Officer, Dr. Edward Kaye, would be resigning.
Stoke revealed on Tuesday that Kaye would formally exit his position on Wednesday. Meanwhile, board associate Ian Smith will assume the role of temporary CEO while the business seeks a lasting substitute. Kaye will remain as an advisor until the handover is finished.
This business is centered on creating therapies for ailments such as Dravet syndrome, an intense kind of seizure disorder that impacts babies.
In a distinct declaration on Tuesday, Stoke issued its Q4 2024 income statement. The business recorded income of $22.61 million, considerably beyond the $4.22 million projected by experts surveyed by Visible Alpha. The company’s deficit per share was $0.18, which was also superior to expected.
Stoke stated that it possessed $246.7 million in liquid assets, near-cash assets, and tradable bonds at the close of the year. With an added $165 million obtained this month from a fresh partnership payment from Biogen (BIIB), the business trusts it possesses adequate capital to sustain its operations until the middle of 2028.
Stoke’s share value declined by almost 3% on Tuesday, but it’s still increased by over 40% during the last year. Ethereum ETFs Face Challenges with $53 Million Outflow, While Bitcoin ETFs Recover
